- NewsCategory：
- All Company news Industry news
common83One result
-
1017
WindMIL Therapeutics and University of Califor±↓↕εnia, Irvine Announce Collaboration>≠ to Collect Bone Marrow from Patients wi✘&✘th Gliomas
WindMIL Therapeutics and University of C₹ε♠↕alifornia, Irvine Ann'✘ounce Collaboration to Co•'→®llect Bone Marrow from Patients with Gliomas✘÷WEDNESDAY, OCTOBER 16, 2019WindM↕IL Therapeutics and the University of Califorε↑Ω>nia, Irvine (UCI) today announced "≤™that the first patients have₹♠₹ been identified in an investi✘↑gator-sponsored study for the collection of bΩ∑one marrow from patients with glioma®±•₩s. The study will evaluate generating ma♠ ☆₩rrow infiltrating lymphocytes (MI₽βLs™) for these patients through WindMIL’♣€$s proprietary cellular activatio←'n and expansion proces₩₩ s. The study is being conducted at UCI.“Patiλ≠ents suffering with glioblastoma are i↑¥βn great need of new, promising treatme×αnts that might advance the cur✘∑≠∑rent standard of care,” said Daniela A. Bota, MD ≥, PhD, director of the UCI ε≈Health Comprehensive Brain Tumγor Program, senior associate₽¥→¶ dean for clinical research, UCI Sch£"€ ool of Medicine and clinical director, UC♥₹I Sue & Bill Gross Stem © Cell Research Center. “The University of Calif ↑¥ornia, Irvine is exciΩΩted to play a key role in r$σβesearch that may leaβ<αd to a clinical trial that✔&π> enlists the immune syst✘em in novel ways to fight this terrible÷≠λ disease.”Gliomas ar®•☆e the most common of the malignant " ₩₹brain tumors. Glioblastoma, β the most common glioma, has a fiv →e-year survival of less than 5¥×& percent. Additional treatment op♦₹€tions are urgently needed for these patients. A ≈&doptive immunotherapΩεαy is a possible approaδ₩↓★ch for gliomas and the use of∞₽ MILs, a cell therapy that is naturalΩ™ly tumor-specific, i★®♥s one such treatment option.The boπ↕★≠ne marrow is a uniqu∏ e niche in the immune system to which ant ±★igen-experienced memory T cells traffic and are "£$then maintained. WindMIL×♣δ has developed a proprietary process to se©÷¥lect, activate and expa✔λnd these memory T cells into Ω☆MILs. Because memory T cells in bone mβπφ∞arrow occur as a result of the ♠✔©'immune system’s recognition of tumor antigens↔€¥¥, MILs are specifically suited for adoptiβ≤ve cellular immunotherapy and are able to direc✔←tly eradicate or facilitate er§®♣adication of each patient’s unique cancer. W™γ±±indMIL is currently studying MILs in multi₽₹&ple myeloma, non-small cell lung can₹cer and squamous cell carci ♣±♣noma of the head and neck, and ®♣←plans to expand into other solid tumors.“WindMIL < is looking forward to working with t☆€βhe University of Cal✘←ifornia, Irvine on this exciting project εαand is optimistic that MILs may offer the potentγ∏¥←ial to help patients wi↔&th these hard-to-treat diseases,”☆↑ said Monil Shah, PharmD, MBA, Chπ₩ ¥ief Development Officer at WindM$®♣≥IL.information source:pharma focus As'φ 'iaThe original link:https://www.pharmafocusasia¶Ω.com/news/windmil-therapeutics∏★₩¶-and-university-of-california-irvine-announce-cπ₹εollaboration-to-colle¥©₽ct-bone-marrow-from-patien→↑σts-with-gliomas2019 Asia-pacific pharma IP Lea®φder Summit: http://en.zenseegroup.com/p/510®±÷934/will be held in ×≤↑×Beijing o₹↔n November 14-15, and will attract m•<<ore than 500 industry experts from domestic an≤ ♠✔d foreign pharmaceutical co"αγmpanies, biotechnology compan÷•ies, governments, associations,∏"¥σ law firms, intellectual property↓♦€ agents and other companies to attend.Official r≤♥egistration and consul★₩← tation channels:Contact：AnnPhone: 0γβ21-65650305Email：Marketing@zenseeβγ group.comhttp://en.zenseegroup.com/p/510934/£×← -
1016
CRISPR Therapeutics a∞♣nd KSQ Therapeutics Announce License Agreementε♥ δ to Advance Companies’ Res "∑pective Cell Therapy Pro$↑grams in Oncology
CRISPR Therapeutics and KSQ Therape≤±utics Announce License Agreement to Advanc÷β'e Companies’ Respective Cell Th™Ωerapy Programs in OncologyWEDNESDAY, OCTOBER 1 6, 2019CRISPR Therapeutics, a bio♠÷γ♥pharmaceutical company focused on c<ε☆ reating transformative↑>↔ gene-based medicines for serious diseases, and K±ΩSQ Therapeutics, a biote$™chnology company using CRISPR t₩₹echnology to enable the c✘™σompany’s powerful drug discovery e★λ♦ngine to achieve higher probabilities of γ≥≤&success in drug deve'•✘lopment, today announced a license agreeme₩$±↑nt whereby CRISPR Therapeu∏×$tics will gain access to KSQ intellectu₽€♠al property (IP) for editing certai¥εn novel gene targets in iקts allogeneic oncology cell therεδ™apy programs, and KSQ will gai$ n access to CRISPR Therapeutics’ IP for ediβ≈ting novel gene targe↕•ts identified by KSQ as part of its curr₩"¶ent and future eTILTM ("≈engineered tumor infiltrating₽αα₹ lymphocyte) cell programs.εΩ÷≈ The financial terms of the&÷↑ agreement are not being dis<®closed.“We are thrilled to g&¥ain access to CRISPR Therapeutics’ foundational£≈↓∑ IP estate through th∑ε∏is agreement,” said Da÷→ vid Meeker, M.D., Chief Ex×α₩←ecutive Officer at KSQ Therapeutics. “Our eTIL★φ÷TM programs involve editin€α¥g gene targets in human TILs that ≥ were discovered at KSQ by applying our proprie₹∑±tary CRISPRomics® approach to immune cel∑←δ₩ls in multiple in vivo models. This agreemenΩ$t clears an important path for us to be able to€δ bring these programs through developm↔ ent and commercialization, leve™±raging CRISPR Therapeutics’ proprietary editin ♠©&g technology.”The gene targets within the scope o'f the license agreement ★•☆were identified using ₹£KSQ’s proprietary CRISPRomics® dru× g discovery engine, which allows genome-sca> le, in vivo validated, unbiased drug discovery. T σhese specific targets were uncovered in screeπ$σns to identify genetic "φ'edits that could enhance the f÷ £§unctionality and quality of aε♣≈doptive cell therapies in oncology.“KSQ has bui$£♠©lt an industry-leadin↑↔g platform to screen for novel gene tar'✘gets using its technology, and has identif ♣$ied a group of targets that could helpσ☆ unlock the full potentia✔"↔σl of adoptive cell therapy in oncolo$∏gy,” said Samarth Kulkarni, Ph.D.,&× Chief Executive Officer &δ±at CRISPR Therapeutics. “As a result of ®•this license agreement, CRISPR The∏®≤♦rapeutics will have the oβ☆₹pportunity to bring these ♦ novel targets into our leading ™£>≈allogeneic CAR-T development plγ™atform to further stre✔εngthen our future progra'→₹ ms in this important t<$®♠herapeutic area.”information source:ph↑arma focus AsiaThe o<¥riginal link:https:https://www.pharmafπ"↕ocusasia.com/news/crisφ♦±pr-therapeutics-and-ksq-therapeutε♠λ↑ics-announce-license-agφπ$reement-to-advance-com"☆panies-respective-cell-therapy-progr©®Ωams-in-oncology2019 A≤sia-pacific pharma IP Le♠<♠ader Summit: http://en.zense γ∏egroup.com/p/510934/ will be held in&nbs¶φp;Beijing on N¶≈₹ ovember 14-15, and wi÷γ™ll attract more than 50∑γ™0 industry experts from domesti→c and foreign pharmaceutical companies, biot↕©echnology companies, governments, ass'¥ociations, law firms, intellectual α₹property agents and other companies to att®α∞♣end.Official registra←® tion and consultation channels:Contact：AnnPhonπ♣≈→e: 021-65650305Email：Mark←★>®eting@zenseegroup.comhttp://e☆φn.zenseegroup.com/p/510934/ -
1015
Shionogi enters into a new license agreement and±δγ research collaboration for the treatment of±φ¶ mycobacterial diseases with Hsiri Th ©≈ erapeutics, Inc.
Shionogi enters into a new license agreeme∑γnt and research collaboration©÷β for the treatment of mycobacterial dis→→®©eases with Hsiri Therapeutics, Inc.•↓÷MONDAY, OCTOBER 14, 2§✔019Shionogi & Co., Lt∑<™d. today announced that it has entered into aπ✔ new license agreement w↑₽ith Hsiri Therapeutics, Inc. (Hea'€d Office: Media, PA,σπ USA; President and CEO: W≠illiam Claypool, M.D.; hereafter "Hsiri") rφγβ↔egarding a collaborative ∞♥★'research and development progr→&δ÷am to discover and d©♣∞evelop additional novel therapeutics ε"for non-tuberculous mycobacterial (NTM) diseases ₹™and tuberculosis (TB). This new colφ"©laboration will include technology that compleme±₽nts Shionogi's earlier collaborat★↓¶ion arrangement with Hsiri.The new technology to∞σ be licensed from Hsi<< σri has a novel mechanism of act←♠ion, will be complementary to Shionogi↑¶'s current research with Hsiri, and is antici≥≤φpated to be more effective than curr→<ent therapies for mycobacterial infect₹"★₽ions. Shionogi's strength in small molecule dr♣₽ €ug discovery and development i≤↓ n the antibacterial area will support dev≥≠πelopment of Hsiri's inπλγ±novative therapeutics in thiε±s collaborative program. Under the terms >σδof this agreement, Shionogi will hβ®↔λave exclusive worldwide rights t≠★&Ωo develop, manufacture, and commercial€'∞λize the compounds generated from the coll€©aboration. Hsiri will receive an upfron₩↕t license fee, potential develop★↑"ment milestones, and royalty payme÷ ✔πnts based on sales from Shionog≠↕i.It is reported that the number of patients s✘βuffering from NTM diseases has been i ×£ncreasing, especially in $≤±developed countries, in recent ∑αyears. There is a medical need to develop novel a♠♠Ωnti-NTM drugs because of the long duration of<™∏ treatment and insufficient treat•↓ment outcome of current the±λδrapeutics. TB is one of the thre< <≥e major infectious diseases in th¶$>e world, and new cases of TB are estimated to ↔¶© be 10.4 million/year. Multidrug-resistant÷> ∞ TB (MDR-TB) and extensively drug-r♥©&esistant TB (XDR-TB) have become a major public h★♦ealth concern, and novel drugs for MD§✔♣R-TB and XDR-TB are antic₩₽₽£ipated.Shionogi's research and developmenβλt targets infectious≠§✔ disease as one of its priority arβ eas, and Shionogi have posit∏>×ioned "protecting people from the'₽" threat of infectious diseas©λes" as one of its social σ∑>↑mission targets. Through this cooperation, S×✘ 'hionogi strives constantly to brin♠<≤g forth innovative drugs for★∏≠∏ the treatment of infectious diseases, to prot♥♣ect the health of pa∑♠βtients we serve.information&"★nbsp;source:pharma focus Asi₽÷aThe original link:htΩ₹♠♣tps:https:https://www.ph∞&≈armafocusasia.com/news/shβ€ionogi-enters-into-a-new-license-agreement-and-'↔≥research-collaboration-for-the-trea×↑™tment-of-mycobacterial-diseases-with-hsiri-β♥therapeutics-inc2019 Asia-pacific pha↓≈™±rma IP Leader Summit: http://en.zenseegroup.com∑</p/510934/ will☆÷ be held in Beijing &nbε≤sp;on November 14-15, and will a™ ₩ttract more than 500 industry experts from dom→ estic and foreign pharmac₽₩♣&eutical companies, biotechnology companies, g©±✘overnments, associati↔₩ons, law firms, intellectual property &∑£agents and other companies to attend.Oφ$π fficial registration and consultation π↔channels:Contact：AnnPhone: 021-65650305EmailΩ ：Marketing@zenseegroup.comhttp://en.zense≤± egroup.com/p/510934/ -
1014
Advaxis and UCLA Enter Collaborat §ion for Glioblastoma Immunotherapy Discove€↔ ry Research
Advaxis and UCLA Enter Collaboration for Gliob§∑∞↓lastoma Immunotherapy Disc>★≠overy ResearchFRIDAY, OCTOBER 11, 2019Advaxγ is, Inc., a clinical-stage biote'×∑¥chnology company focused on€₩←' the discovery, development and commerc§Ω§ialization of immunotherapy prod±♠ucts, today announced a♥Ω research collaboration ag"≤λreement with the University of Californi≈♠a Los Angeles (UCLA) to condu ↔ct preclinical studies evaluating the π•Company’s Lm technology in mouse tumor models of∞©✘ glioblastoma multifo¥☆rme (GBM). Specifically, th≤©e collaboration with Dr. Vaithi Arumuγ $gaswami’s group at UCLA’s Department×∑β of Molecular and Medical Phar☆δΩmacology will investigate anti-tumor immunit♥<y and anti-tumor responses generated by ¶≠×Lm vaccines that express dive ↕rse glioblastoma neoantigens.“We are excited that¶→ Dr. Arumugaswami and his col₽δleagues at UCLA will investigate &σ✘the potential of our Lm technology p±∏"latform in GBM, one of the deadlie<∞"st cancers,” said Andres Guti >φerrez, Executive Vice P ¥>resident and Chief Medical× Officer of Advaxis. “Contrary to₩™ other tumor types, G∞ΩBM has not seen much success in targeti"&δng by immunotherapeutic a♥γ®gents due to a low tumor muta¥£☆tion burden, high tumor ↔heterogeneity and presence of the blood bra≤♦™§in barrier, among other factors. Hence, Dr♥. Arumugaswami’s char>π∑acterization of the neoantigen la©↓>↑ndscape and immune responses to Lm- constr$€ucts may lead to the development of novel therapi♣< ✘es with clinical activity in this←© elusive cancer.”information source:pharma '✘focus AsiaThe original link:https:http→<♦s:https://www.pharmafocusasia.com/news/adΩεvaxis-and-ucla-enter-collaboration-for-glioblas'₽toma-immunotherapy-discover&±y-research2019 Asia-pacif§£λic pharma IP Leader S©∏ummit: http://en.zenseegrouα←¥p.com/p/510934/will be held in Beiji>←ng on&nbs→δαp;November 14-15, and will attract more than 50®>0 industry experts from domestic and foreign<∏ pharmaceutical compan★±γies, biotechnology companie∑♣✘s, governments, associaφ¶¶tions, law firms, intellectual proper✔₹↑ty agents and other •∏companies to attend.Official registration and ×←♣consultation channel≥ s:Contact：AnnPhone: 021-65650305Email：Marketi'×ng@zenseegroup.comhttp://en.zense♥×δ£egroup.com/p/510934/ -
1011
Viela Bio Enters Strategic Collaboration w≥←ith Mitsubishi Tanabe Pharma to Develop and Comm₩∑λercialize Inebilizumab for Aut≥oimmune Diseases in Japan and Other Asia Re←♠gions
THURSDAY, OCTOBER 10, 2019Viela Bio, ♦≥Inc. and Mitsubishi Ta•₽nabe Pharma Corporation (“MTPC”) tod∑∞πay announced a collabo∏↕∏ration focused on the developmen€✔σt and commercialization of iβ™δ•nebilizumab – Viela’φπδ★s humanized anti-CD19 monocl ☆₽±onal antibody – in nine Asia regionsγ♦ for neuromyelitis optica s >αpectrum disorder (NMOS•≤D), as well as other potential future ind↕↕ications.“This partnership adds₽ ≥γ to our ability to commercialize inebiliz" βumab globally, subject to regulat&♦λory approval,” commented Bing Yao, Ph.D., V←iela’s Executive Chairmanα÷☆≠ and Chief Executive Officer. “As a wel÷ l-established pharmaceutical company in Japan, Mi∞∑tsubishi Tanabe has strong produ∑ct development and c≈≠ommercialization cap♥↓λ•abilities in Asia, and we believe, ☆ ₩is an ideal partner fo'βr expanding inebilizumab’s potential reach "× to thousands of additional patients ∞★©in need of viable treatments, with NM≈ '&OSD as an initial indi✘✔≈cation.”Under terms of the collaborationε♥, Viela will receive an up-front licensing÷₹¥ fee of $30 million as well as addiδ "✔tional payments conti₽γ↕ngent on certain development and comm♦β§ercial milestones, plus payment≠ φs based, in part, on sales re∑↔→venue. MTPC will be responsible for leadiε×βng development and commerci♣ €λalization of inebilizΩ'≥umab in Japan, Thail ♥∞↑and, South Korea, Indonesia, Vi★¶×etnam, Malaysia, Philippines ↓₩, Singapore, and Taiwan.“Ou¶↓r organization is delighted €σ>≠to partner with Viela to develop and commerc♣↓€ialize their promising product candidλ∞ate inebilizumab for autoimmune and inf↓•σlammatory diseases,” said Masayσ© ↕uki Mitsuka, MTPC President & Repr§↑esentative Director. “Inebilizumab is©± an exciting product±♠" candidate that, based on the results from t≤σ✔he N-MOmentum pivotal ↓&♥←study, is well-position€§ed to provide meaningful be¥✔↕nefit for patients with NMOSD, an'λd potentially additional diseases,≥≤'♥ subject to regulatory approval. We are e&∏xcited to work with Viela to adva₹←nce inebilizumab in Japan and other Asia r§↓♣egions, and look forward to a pr•★✔€oductive partnership between our companies.”Th ™¥e U.S. Food and Drug Admin<₩istration (FDA) recently accep™☆ted for review Viela&€↔✘’s Biologics License Application (BLA•γ™ ) for inebilizumab for the tr®₹βeatment of NMOSD. information&n↑γ©bsp;source:pharma focus✔ ₹ AsiaThe original link:http±¥ s:https://www.pharmafocusasia.com/news/₩±viela-bio-enters-strategic-collabor£ation-with-mitsubishi-tanabe-pharma-to-d"☆>∞evelop-and-commerciali↔εαze-inebilizumab-for-autoimmune-dis★πeases-in-japan-and-oth±↔ er-asia-regions2019 Asia-pacific pharma I≠αP Leader Summit: http://en.zenseegroup.com/p/&"510934/will be held in Beijing on"← November 14-15, and will₩ ✔ attract more than 500 industry experts from dom↔$estic and foreign pharmaceutical compa≠γnies, biotechnology companies, governments, aδssociations, law firms, intel'£©↑lectual property agents and other £"♠companies to attend.Official registr↓₹ation and consultation channels:Contact：A§πnnPhone: 021-65650305Email：Marketin ≈ g@zenseegroup.comhttp://en.zenseegroup.com/p/5109®✘♦♣34/
Contact Us
Zensee_Daystar online
© 2011-2016